Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 467-483 , September 2008

Use of natural killer cells as immunotherapy for leukaemia

References 

  1. Kiessling R, Klein E, Wigzell H. ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. European Journal of Immunology. 1975;5:112–117
  2. Lanier LL, Phillips JH, Hackett J, et al. Natural killer cells: definition of a cell type rather than a function. Journal of Immunology. 1986;137:2735–2739
  3. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306:1517–1519
  4. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature. 1992;358:66–70
  5. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class-I molecules in human natural killer cells. Annual Review of Immunology. 1996;14:619–648
  6. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:5199–5204
  7. Stern P, Gidlund M, Orn A, et al. Natural killer cells mediate lysis of embryonal carcinoma cells lacking MHC. Nature. 1980;285:341–342
  8. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. The Journal of experimental medicine. 1971;134:1513–1528
  9. Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678
  10. Lanier LL. NK cell recognition. Annual Review of Immunology. 2005;23:225–274
  11. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunological Reviews. 2001;181:170–184
  12. Gazit R, Gruda R, Elboim M, et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nature Immunology. 2006;7:517–523
  13. Arnon TI, Lev M, Katz G, et al. Recognition of viral hemagglutinins by NKp44 but not by NKp30. European Journal of Immunology. 2001;31:2680–2689
  14. Young JD, Hengartner H, Podack ER, et al. Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell. 1986;44:849–859
  15. Zamai L, Ahmad M, Bennett IM, et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. The Journal of Experimental Medicine. 1998;188:2375–2380
  16. Loza MJ, Zamai L, Azzoni L, et al. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood. 2002;99:1273–1281
  17. de Landazuri MO, Silva A, Alvarez J, et al. Evidence that natural cytotoxicity and antibody-dependent cellular cytotoxicity are mediated in humans by the same effector cell populations. Journal of Immunology. 1979;123:252–258
  18. Binstadt BA, Brumbaugh KM, Dick CJ, et al. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity. 1996;5:629–638
  19. Lanier LL, Corliss BC, Wu J, et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391:703–707
  20. Colonna M, Borsellino G, Falco M, et al. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:12000–12004
  21. Gumperz JE, Litwin V, Phillips JH, et al. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. The Journal of Experimental Medicine. 1995;181:1133–1144
  22. Wende H, Colonna M, Ziegler A, et al. Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mammalian Genome. 1999;10:154–160
  23. Shilling HG, Guethlein LA, Cheng NW, et al. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. Journal of Immunology. 2002;168:2307–2315
  24. Pando MJ, Gardiner CM, Gleimer M, et al. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. Journal of Immunology. 2003;171:6640–6649
  25. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753–763
  26. Shilling HG, Young N, Guethlein LA, et al. Genetic control of human NK cell repertoire. Journal of Immunology. 2002;169:239–247
  27. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. The Journal of Experimental Medicine. 2006;203:633–645
  28. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–799
  29. Kaiser BK, Barahmand-pour F, Paulsene W, et al. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. Journal of Immunology. 2005;174:2878–2884
  30. Shum BP, Flodin LR, Muir DG, et al. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. Journal of Immunology. 2002;168:240–252
  31. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739–751
  32. Draghi M, Yawata N, Gleimer M, et al. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood. 2005;105:2028–2035
  33. Fernandez NC, Treiner E, Vance RE, et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105:4416–4423
  34. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331–342
  35. Cooley S, Xiao F, Pitt M, et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood. 2007;110:578–586
  36. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709–713
  37. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annual Review of Immunology. 2001;19:291–330
  38. Johansson MH, Hoglund P. The dynamics of natural killer cell tolerance. Seminars in Cancer Biology. 2006;16:393–403
  39. Bryceson YT, March ME, Ljunggren H-S, et al. Activation, coactivation, and costimulation of resting human natural killer cells. Immunological Reviews. 2006;214:73–91
  40. Grzywacz B, Kataria N, Sikora M, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006;108:3824–3833
  41. Freud AG, Yokohama A, Becknell B, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. The Journal of Experimental Medicine. 2006;203:1033–1043
  42. Davies GE, Locke SM, Wrigh PW, et al. Identification of bidirectional promoters in the human KIR genes. Genes and Immunity. 2007;8:245–253
  43. Shilling HG, Mcqueen KL, Cheng NW, et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood. 2003;101:3730–3740
  44. Zimmer J, Donato L, Hanau D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). The Journal of Experimental Medicine. 1998;187:117–122
  45. Markel G, Mussaffi H, Ling K-L, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood. 2004;103:1770–1778
  46. Iizuka K, Naidenko OV, Plougastel BF, et al. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nature Immunology. 2003;4:801–807
  47. Lee KM, McNerney ME, Stepp SE, et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. The Journal of Experimental Medicine. 2004;199:1245–1254
  48. Hoglund P, Ohlén C, Carbone E, et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proceedings of the National Academy of Sciences of the United States of America. 1991;88:10332–10336
  49. Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. Journal of Immunology. 1986;136:4480–4486
  50. Chan A, Hong D-L, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. Journal of Immunology. 2007;179:89–94
  51. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  52. Chewning JH, Gudme CN, Hsu KC, et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. Journal of Immunology. 2007;179:854–868
  53. Koh CY, Ortaldo JR, Blazar BR, et al. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood. 2003;102:4067–4075
  54. Street SE, Hayakawa Y, Zhan Y, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. The Journal of Experimental Medicine. 2004;199:879–884
  55. Murphy WJ, Koh CY, Raziuddin A, et al. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunological Reviews. 2001;181:279–289
  56. Jager MJ, Hurks HM, Levitskaya J, et al. HLA expression in uveal melanoma: there is no rule without some exception. Human Immunology. 2002;63:444–451
  57. Orange JS. Human natural killer cell deficiencies. Current Opinion in Allergy and Clinical Immunology. 2006;6:399–409
  58. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957–1959
  59. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389–1396
  60. Lowdell MW, Ray N, Craston R, et al. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplantation. 1997;19:891–897
  61. Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. British Journal of Haematology. 2002;117:821–827
  62. Tajima F, Tajima F, Kawatani T, et al. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia. 1996;10:478–482
  63. Siegler U, Kalberer CP, Nowbakht P, et al. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia. 2005;19:2215–2222
  64. Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109:323–330
  65. Yoda Y, Abe T, Tashiro A, et al. Normalized natural killer (NK) cell activity in long-term remission of acute leukaemia. British Journal of Haematology. 1983;55:305–309
  66. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. The New England Journal of Medicine. 1987;316:889–897
  67. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplantation. 2003;32:177–186
  68. Smyth MJ, Teng MWL, Swann J, et al. CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. Journal of Immunology. 2006;176:1582–1587
  69. Leung W, Handgretinger R, Iyengar R, et al. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. British Journal of Cancer. 2007;97:539–542
  70. Koh CY, Blazar BR, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood. 2001;97:3132–3137
  71. Hallett WH, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. Journal of Immunology. 2008;180:163–170
  72. Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Experimental Hematology. 1999;27:1533–1541
  73. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration–effect relationship. Cancer Research. 2004;64:4664–4669
  74. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the children's oncology group. Clinical Cancer Research. 2006;12:1750–1759
  75. Davis ID, Skrumsager BK, Cebon J, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clinical Cancer Research. 2007;13:3630–3636
  76. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57–63
  77. Roda JM, Parihar R, Carson WE. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. Journal of Immunology. 2005;175:1619–1627
  78. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. Journal of Immunology. 2005;174:727–734
  79. Stary G, Banger C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. The Journal of Experimental Medicine. 2007;204:1441–1451
  80. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–339
  81. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100:3825–3827
  82. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biology of Blood and Marrow Transplantation. 2006;12:876–884
  83. Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biology of Blood and Marrow Transplantation. 2007;13:315–328
  84. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819
  85. Penack O, Fischer L, Gentilini C, et al. The type of ATG matters – natural killer cells are influenced differentially by thymoglobulin, lymphoglobulin and ATG-Fresenius. Transplant Immunology. 2007;18:85–87
  86. Gattinoni L, Finkelstein SF, Klebanoff A, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. The Journal of Experimental Medicine. 2005;202:907–912
  87. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057
  88. Wang H, Grzywacz B, Sukovich D, et al. The unexpected effect of cyclosporin A on CD56+ CD16- and CD56+ CD16+ natural killer cell subpopulations. Blood. 2007;110:1530–1539
  89. Vitale C, Chiossone L, Cantoni C, et al. The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. European Journal of Immunology. 2004;34:3028–3038
  90. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63:204–211
  91. Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106:4370–4376
  92. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology. 2004;172:644–650
  93. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–4884
  94. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058–5061
  95. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006;107:1688–1695
  96. Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood. 2001;98:705–713
  97. Fischer JC, Ottinger H, FerenciK S, et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. Journal of Immunology. 2007;178:3918–3923
  98. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. 2006;107:1230–1232
  99. De Santis D, Bishara A, Wit CS, et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens. 2005;65:519–528
  100. Verheyden S, Schots R, Duquet W, et al. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005;19:1446–1451
  101. Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006;82:1024–1030
  102. McQueen KL, Dorighi KM, Guethlein LA, et al. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Human Immunology. 2007;68:309–323
  103. Gagne K, Brizarda G, Guegliob B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Human Immunology. 2002;63:271–280
  104. McKenna DH, Sumstad D, Bostrom N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47:520–528
  105. Koehl U, Esser R, Zimmermann S, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klinische Pädiatrie. 2005;217:345–350
  106. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. The Journal of Clinical Investigation. 1998;101:1835–1842

PII: S1521-6926(08)00064-9

doi: 10.1016/j.beha.2008.07.008

Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 467-483 , September 2008

Article Tools

* Image Usage & Resolution